Diabetes News

Endocrinology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Henry RR et al. – Short-term clinical data show a favorable safety and efficacy profile for the dual peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonist aleglitazar.

Methods

Results


Related Articles

Prevention of Type 2 Diabetes: Risk Status, Clinic, and Community
Journal of General Internal Medicine, 11/09/09    Relevance Score: 96%

Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 10/19/09    Relevance Score: 95%

Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study
Clinical Endocrinology, 10/16/09    Relevance Score: 94%

Periodontal Disease – The Overlooked Diabetes Complication
Nephrology Nursing Journal, 10/07/09    Relevance Score: 94%

Testing for monogenic diabetes among children and adolescents with antibody-negative clinically defined Type 1 diabetes
Diabetic Medicine, 10/05/09    Relevance Score: 94%

Today in Basic Science/Genetics...keeping you current

Immunological detection of fructose-derived advanced glycation end-products
Laboratory Investigation, 03/19/10

Involvement of Estrogen Receptor Variant ER-[alpha]36, Not GPR30, in Nongenomic Estrogen Signaling
Molecular Endocrinology, 03/19/10

The Transcription Factor ATF4 Promotes Skeletal Myofiber Atrophy during Fasting
Molecular Endocrinology, 03/19/10


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address